---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-046651"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:05:24.044110+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AlloVir appoints Derek Adams to board; Ansbert Gadicke retires

## Summary
- Derek Adams, Ph.D. appointed to Board effective March 1, 2023, filling vacancy from Ansbert Gadicke's retirement.
- Dr. Adams brings over 20 years of experience in manufacturing biologic and gene therapies; currently CEO of Stellular Bio.
- Ansbert Gadicke, M.D. retires from board effective February 28, 2023; no disagreement with company.
- AlloVir is a late-clinical stage allogeneic T cell immunotherapy company with three ongoing Phase 3 studies for posoleucel.

## SEC filing metadata
- accession: 0001193125-23-046651
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/d317019d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-046651
- JSON: https://secwatch.observer/filing/0001193125-23-046651.json
- Plain text: https://secwatch.observer/filing/0001193125-23-046651.txt

## Key facts
- Executive change
  Ansbert Gadicke retired as Director at Kalaris Therapeutics, Inc..
  - Action: retired
  - Role: Director
  source text: Ansbert Gadicke, M.D. notified the Board that he will be retiring from the Board effective February 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm
- Executive change
  Derek Adams was appointed as Director at Kalaris Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Derek Adams, Ph.D. to the Board, effective March 1, 2023, to fill a newly created vacancy resulting from the retirement of Ansbert Gadicke, M.D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.